ORCHESTRA BIOMED HOLDINGS IN

Orchestra BioMed’s recent insider sales show a disciplined rule‑based trading plan, not a sell‑off. The biotech’s strategic collaborations and Phase II pipeline keep upside potential alive amid a flat share price.

Orchestra BioMed insider sale: 15k shares sold under a Rule 10b5‑1 plan at $4.27—routine liquidity move amid rising stock, not a sign of distress.

Insider CFO Taylor Andrew Lawrence sold 36,352 Orchestra BioMed shares at $4.02 per share— a routine RSU‑driven move with negligible impact on the stock’s price or valuation.